Abstract

Despite strong evidence linking amyloid beta (Aβ) to Alzheimer's disease, most clinical trials have shown no clinical efficacy for reasons that remain unclear. To understand why, we developed a quantitative systems pharmacology (QSP) model for seven therapeutics: aducanumab, crenezumab, solanezumab, bapineuzumab, elenbecestat, verubecestat, and semagacestat.

Authors

Kumpal Madrasi, Raibatak Das, Hafiz Mohmmadabdul, Lin Lin, Bradley T. Hyman, Douglas A. Lauffenburger, Mark W. Albers, Robert A. Rissman, John M. Burke, Joshua F. Apgar, Lucia Wille, Lore Gruenbaum, Fei Hua

Leave site to read publication >>